Dicerna Pharma (DRNA) Misses Q4 EPS by 13c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Dicerna Pharma (DRNA) Misses Q4 EPS by 13c, Beats on Revenues
March 9, 2018 9:45 AM EST
SunTrust Robinson Humphrey raised its price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $15.00 (from $13.00) while maintaining a Buy rating.
Analyst Edward Nash commented, "Yesterday, after the close, Dicerna reported FY2017 financials and provided a corporate update. We are incrementally more positive as... More
March 9, 2018 7:47 AM EST
Chardan Capital Markets initiates coverage on Dicerna Pharmaceuticals (NASDAQ: DRNA) with a Neutral rating saying new investors should wait for a more attractive entry point.
Analsyt Keay Nakae commented, "We believe that Dicerna has the potential to become a significant competitor in the... More
March 9, 2018 5:55 AM EST
Stifel raised its price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $17.00 (from $10.00) while maintaining a Buy rating.
Analsyt Stephen Willey commented, "We continue to like the trajectory of the DRNA story as DCR-PHXC now looks poised for the initiation of a... More
